Targeting resistant breast tumors using specialized nano-capsids
Targeting inhibitor-resistant breast tumors with HER3-homing nano-capsids
This study is testing a new treatment for breast cancer that doesn't respond to regular therapies, using tiny particles that can deliver medicine directly to the cancer cells, aiming to help patients with tough-to-treat tumors feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11042158 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for breast tumors that have become resistant to existing therapies. It utilizes specially designed nano-capsids that target the HER3 receptor, which is often elevated in these resistant tumors. By delivering toxic molecules directly into the cancer cells, this approach aims to overcome the limitations of current treatments and provide a more effective option for patients with difficult-to-treat breast cancer. The methodology involves using a self-assembling nanobiological particle called HerDox, which can enter tumor cells and induce cell death while minimizing damage to healthy tissues.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast cancer that has shown resistance to standard therapies, particularly those with elevated HER3 levels.
Not a fit: Patients with early-stage breast cancer that has not developed resistance to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with inhibitor-resistant breast tumors, potentially improving their prognosis.
How similar studies have performed: Previous research has shown promising results with similar targeted approaches, indicating potential for success in this novel application.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Medina-Kauwe, Lali K — Cedars-Sinai Medical Center
- Study coordinator: Medina-Kauwe, Lali K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.